 |
|
Join the IVC Network on LinkedIn
|
|
Become an IVC fan on Facebook
|
|
|
|
|
|
| Kamada raises further NIS 6 million | Published by: Globes
www.globes.co.il
Gali Weinreb
10/05/2009
| The latest investment follows the $7 million that the company raised last week.
Biopharmaceutical company Kamada Ltd. (TASE:KMDA) today announced that it had expanded its latest round of fund raising with a NIS 6 million investment from Meitav Provident and Pension Fund Ltd. And from Meitav Mishan Provident Fund Management Ltd.
Last week Kamada reported that it had raised $7million from its founder Ralph Hahn and investment group UDT Med Holdings and that it was open to an additional $15 million in investments by June.
Kamada CEO David Tsur said that the company was conducting a kind of road show to Israeli institutional investors in order to raise investment to fund its upcoming and final clinical trial before marketing its Alpha-1 Antitrypsin (AAT) product for treating respiratory diseases.
|
Close Window
|
 |
Previous article Next article
|
|
|
 |
|
The most complete volume
of Israel’s high-tech & venture capital industry.
The yearbook includes data on Israeli technology companies, VC investors and more.
|
|
